 |
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Welcome to Small Cap Profits .com
Smallcapprofits.com is dedicated to getting your company’s voice heard. In this fast-paced market, Small Cap and OTC companies can easily be overlooked. Without the resources and funding of Fortune 500 firms, it can be difficult to maintain a consistent presence in the public’s eye. Smallcapprofits.com can help! At Smallcapprofits.com we believe in disseminating real news. You won't find the hype some sites try to present as news. Our goal is to gain exposure for our client companies through our Internet interviews (Webcasts), conference calls, emails, investor newsletters, and strategic placement on financial web sites. Essentially, we help you tell your story and ensure that story is heard. Smallcapprofits.com provides clients with different levels of services ranging from micro packages to massive investor awareness campaigns, or even a complete investor relations package. Our clients simply choose the level of service they desire and leave the rest to us.Read more
Latest Featured Article Post
Small Cap Profits.com Featured Article: (ECPL)
Dec 4, 2010
Small Cap Profits.com (ECPL)
The company EcoPlus (ECPL) has recently reversed their stock 1 for 200 and issued 40 Billion shares to give it a market cap of $2.8 Billion. This is from a company with $21,000 in sale for the six-month period ending April 30, 2010. Are you kidding me? Recently they changed their state of incorporation from Nevada to Wyoming to avoid any par value taxes to issue 40 Billion shares. What is not clear is what did they receive for the 40 billion shares? and whom were they issued to? Too bad we cant short on the pink sheets.
Small Cap Profits.com Featured Article: (SNBP.OB)
July 21, 2010
Sinobiopharma, Inc. (SNBP.OB)
Sinobiopharma, Inc. is a biopharmaceutical company whose main focus is on anesthesia-assisted agents and cardiovascular drugs. The company announced yesterday that they have entered an agreement with Anhui Xianfeng Pharmaceuticals Co. Ltd (Xianfeng) to manufacture and co-market Clindamycin and L-alanyl-L-glutamine.
Clindamycin is an antibiotic used to treat anaerobic bacterial infections, and is also used as a topical acne treatment cream. Parenteral nutrition product L-alanyl-L-glutamine is prescribed for patients after surgery.
SNBP owns the drug certificates, drug registration approval documents and production technologies of the two products.
Under the agreement, SNBP will make the production technologies available to Xianfeng for a fee. Xianfeng can then use their own manufacturing facilities to lower production costs. SNBP will pay Xianfeng to manufacturing the drugs, and the companies will jointly market the products.
“Xianfeng has the GMP-certified facilities for the production of Clindamycin and L-alanyl-L-glutamine and is a strong marketing partner,” Dr. Lequn Lee Huang, chairman and CEO of Sinobiopharma stated in the press release. “We expect production to start later this year and are confident this cooperation will help fuel the continued growth of Sinobiopharma.”
